patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_343811 | REC_0010401 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 16.7 | 63 | male | 1 | 20 | 6.1 | 4 | osimertinib 80 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:59.450655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767805 | REC_0010402 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 12.6 | 66 | male | 1 | 13 | 3.9 | 5 | sotorasib 960 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:35:59.450897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491285 | REC_0010403 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.1 | 67 | female | 0 | 6 | 4.3 | 6 | osimertinib 80 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:59.451133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838396 | REC_0010404 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3 | 55 | female | 1 | 68 | 4.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:35:59.451368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194853 | REC_0010405 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 15.7 | 68 | male | 1 | 16 | 4.9 | 8 | alectinib 600 mg BID | 16.9 | false | MSS | 2026-03-15T05:35:59.451605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605400 | REC_0010406 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 7.1 | 69 | female | 1 | 18 | 6.4 | 5 | sotorasib 960 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:59.451847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988682 | REC_0010407 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 4.6 | 68 | male | 0 | 15 | 3.5 | 7 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:59.452135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341280 | REC_0010408 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 37 | 14.8 | 73 | male | 1 | 10 | 5.8 | 6 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:59.452394+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426608 | REC_0010409 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 6.7 | 66 | male | 1 | 11 | 7.3 | 1 | osimertinib 80 mg daily | 15 | false | MSS | 2026-03-15T05:35:59.452644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938595 | REC_0010410 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 31 | 11.8 | 69 | male | 0 | 14 | 6.3 | 0 | osimertinib 80 mg daily | 32.2 | true | MSI-H | 2026-03-15T05:35:59.452915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_675029 | REC_0010411 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 14.3 | 60 | female | 1 | 13 | 7.4 | 4 | osimertinib 80 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:59.453209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653483 | REC_0010412 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.8 | 80 | male | 1 | 29 | 5.3 | 6 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:59.453725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417158 | REC_0010413 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 13.6 | 63 | male | 1 | 6 | 6.7 | 6 | entrectinib 600 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:59.454015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307349 | REC_0010414 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.9 | 63 | male | 1 | 7 | 5.4 | 3 | osimertinib 80 mg daily | 16 | false | MSI-H | 2026-03-15T05:35:59.454428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784830 | REC_0010415 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.5 | 72 | female | 3 | 4 | 7 | 5 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:59.454721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673969 | REC_0010416 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 15.5 | 71 | female | 2 | 14 | 4.5 | 3 | osimertinib 80 mg daily | 25.3 | false | MSS | 2026-03-15T05:35:59.454972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655796 | REC_0010417 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 6.1 | 69 | female | 0 | 14 | 3.5 | 6 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:35:59.455219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982012 | REC_0010418 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 14.9 | 61 | male | 1 | 23 | 6.2 | 5 | osimertinib 80 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:35:59.455473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745732 | REC_0010419 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.8 | 80 | female | 1 | 19 | 5.6 | 6 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:59.455716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400309 | REC_0010420 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 14.2 | 66 | female | 1 | 15 | 4 | 2 | sotorasib 960 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:59.455967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319503 | REC_0010421 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 15.5 | 61 | female | 0 | 9 | 4.6 | 2 | alectinib 600 mg BID | 16.4 | true | MSS | 2026-03-15T05:35:59.456312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257232 | REC_0010422 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 12.7 | 77 | female | 2 | 19 | 3.1 | 1 | osimertinib 80 mg daily | 16.2 | true | MSS | 2026-03-15T05:35:59.456579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770042 | REC_0010423 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 16.4 | 77 | female | 0 | 17 | 5 | 2 | entrectinib 600 mg daily | 17.3 | true | MSI-H | 2026-03-15T05:35:59.456830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475501 | REC_0010424 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 16.3 | 72 | female | 1 | 13 | 5.3 | 7 | alectinib 600 mg BID | 12.7 | true | MSS | 2026-03-15T05:35:59.457078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872035 | REC_0010425 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 8.2 | 66 | female | 1 | 19 | 6.9 | 2 | alectinib 600 mg BID | 14.5 | true | MSS | 2026-03-15T05:35:59.457330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894264 | REC_0010426 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.9 | 67 | female | 1 | 21 | 4.6 | 5 | sotorasib 960 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:59.457601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321319 | REC_0010427 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 9.1 | 61 | male | 1 | 19 | 4.3 | 3 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:35:59.457960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150551 | REC_0010428 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 10 | 4.6 | 68 | male | 1 | 61 | 6.6 | 5 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:35:59.458218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825115 | REC_0010429 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.5 | 76 | female | 2 | 20 | 3.6 | 4 | entrectinib 600 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:59.458455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359026 | REC_0010430 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 2.6 | 68 | male | 0 | 46 | 7 | 4 | carboplatin + paclitaxel + pembrolizumab | 4.8 | true | MSS | 2026-03-15T05:35:59.458700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540573 | REC_0010431 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 19.1 | 57 | male | 1 | 7 | 4.2 | 3 | sotorasib 960 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:59.458963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234927 | REC_0010432 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 14.4 | 67 | female | 1 | 17 | 2.9 | 0 | sotorasib 960 mg daily | 27.3 | false | MSS | 2026-03-15T05:35:59.459212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888368 | REC_0010433 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.9 | 62 | male | 1 | 64 | 6.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:35:59.459458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830827 | REC_0010434 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 10.2 | 82 | female | 2 | 3 | 5 | 1 | pembrolizumab 200 mg q3w | 25.3 | false | MSS | 2026-03-15T05:35:59.459704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242741 | REC_0010435 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 13.7 | 55 | male | 0 | 12 | 4.5 | 4 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:59.459946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518786 | REC_0010436 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.9 | 57 | male | 0 | 12 | 4 | 4 | sotorasib 960 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:59.460247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772326 | REC_0010437 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 3 | 44 | male | 0 | 15 | 6.1 | 6 | osimertinib 80 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:59.460521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997639 | REC_0010438 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13.9 | 69 | female | 0 | 14 | 6.7 | 8 | alectinib 600 mg BID | 13.3 | false | MSI-H | 2026-03-15T05:35:59.460799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301014 | REC_0010439 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.8 | 63 | male | 1 | 21 | 7 | 5 | osimertinib 80 mg daily | 9.9 | false | MSI-H | 2026-03-15T05:35:59.461051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331210 | REC_0010440 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 12.8 | 74 | female | 3 | 20 | 3.5 | 0 | osimertinib 80 mg daily | 20.4 | true | MSI-H | 2026-03-15T05:35:59.461425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305785 | REC_0010441 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.2 | 62 | female | 0 | 10 | 6.1 | 6 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:35:59.461680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673440 | REC_0010442 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 20 | 19.6 | 71 | female | 1 | 12 | 3.9 | 0 | entrectinib 600 mg daily | 32.8 | true | MSS | 2026-03-15T05:35:59.461928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254507 | REC_0010443 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 9.7 | 69 | female | 1 | 10 | 5.3 | 1 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:59.462200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800444 | REC_0010444 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.9 | 71 | female | 2 | 10 | 7.7 | 8 | osimertinib 80 mg daily | 8 | true | MSS | 2026-03-15T05:35:59.462450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602120 | REC_0010445 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 5.5 | 84 | female | 2 | 8 | 6.6 | 2 | entrectinib 600 mg daily | 32.7 | false | MSS | 2026-03-15T05:35:59.462680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905876 | REC_0010446 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.1 | 63 | male | 1 | 5 | 6.9 | 4 | entrectinib 600 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:59.462915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927580 | REC_0010447 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 10.8 | 70 | female | 2 | 23 | 5.3 | 7 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:59.463149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218206 | REC_0010448 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 9 | 67 | male | 0 | 16 | 3.1 | 6 | entrectinib 600 mg daily | 7.6 | false | MSS | 2026-03-15T05:35:59.463398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857757 | REC_0010449 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.6 | 67 | female | 1 | 12 | 6.3 | 2 | pembrolizumab 200 mg q3w | 26.1 | true | MSS | 2026-03-15T05:35:59.463630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110169 | REC_0010450 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 16 | 74 | female | 1 | 14 | 6.3 | 8 | osimertinib 80 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:59.463863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229697 | REC_0010451 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.3 | 62 | female | 1 | 17 | 6.8 | 5 | alectinib 600 mg BID | 16 | false | MSS | 2026-03-15T05:35:59.464143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422031 | REC_0010452 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.7 | 69 | female | 1 | 23 | 5.4 | 6 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:35:59.464414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619495 | REC_0010453 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 4.9 | 75 | female | 1 | 57 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:59.464811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180982 | REC_0010454 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.6 | 62 | male | 1 | 52 | 7.6 | 2 | pembrolizumab 200 mg q3w | 19.3 | true | MSS | 2026-03-15T05:35:59.465107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800726 | REC_0010455 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 8.5 | 57 | female | 1 | 16 | 6.2 | 2 | sotorasib 960 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:59.465400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455646 | REC_0010456 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 5.8 | 61 | female | 0 | 34 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.8 | true | MSS | 2026-03-15T05:35:59.465665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243720 | REC_0010457 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 16 | 5.8 | 68 | male | 1 | 50 | 5.6 | 2 | pembrolizumab 200 mg q3w | 19.3 | true | MSS | 2026-03-15T05:35:59.465915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829742 | REC_0010458 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 19.7 | 80 | female | 1 | 28 | 6.4 | 4 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:59.466150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193444 | REC_0010459 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 11.5 | 58 | female | 1 | 23 | 6 | 5 | sotorasib 960 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:59.466390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244704 | REC_0010460 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 18.8 | 73 | female | 2 | 10 | 6.2 | 5 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:59.466623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393127 | REC_0010461 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.8 | 55 | female | 0 | 45 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.9 | true | MSS | 2026-03-15T05:35:59.466861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681739 | REC_0010462 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 16 | 3.7 | 70 | female | 1 | 29 | 3.6 | 1 | pembrolizumab 200 mg q3w | 23 | false | MSS | 2026-03-15T05:35:59.467119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185158 | REC_0010463 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 5.8 | 79 | female | 2 | 29 | 7.5 | 2 | osimertinib 80 mg daily | 20.2 | true | MSS | 2026-03-15T05:35:59.467410+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856118 | REC_0010464 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.1 | 67 | female | 1 | 16 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:35:59.467699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448890 | REC_0010465 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 11 | 5.2 | 73 | female | 1 | 22 | 7.1 | 2 | entrectinib 600 mg daily | 19.1 | true | MSS | 2026-03-15T05:35:59.468003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172159 | REC_0010466 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.9 | 61 | female | 2 | 14 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:35:59.468507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346620 | REC_0010467 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 8 | 55 | female | 1 | 75 | 5.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 16.8 | false | MSS | 2026-03-15T05:35:59.468826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684567 | REC_0010468 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 9.1 | 73 | female | 2 | 26 | 5.8 | 6 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:59.469092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429054 | REC_0010469 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 13.5 | 71 | female | 1 | 10 | 5.2 | 2 | entrectinib 600 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:59.469360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362043 | REC_0010470 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 6.2 | 70 | male | 1 | 9 | 3.7 | 2 | alectinib 600 mg BID | 21.7 | true | MSS | 2026-03-15T05:35:59.469612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141548 | REC_0010471 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.8 | 63 | female | 1 | 48 | 5.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 7.7 | true | MSS | 2026-03-15T05:35:59.469854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350290 | REC_0010472 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 16.5 | 59 | male | 0 | 13 | 7.2 | 2 | entrectinib 600 mg daily | 14 | true | MSS | 2026-03-15T05:35:59.470105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857343 | REC_0010473 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 7.3 | 68 | male | 1 | 15 | 4.3 | 6 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:59.470342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207892 | REC_0010474 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 6.5 | 68 | female | 0 | 18 | 7.2 | 0 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:59.470579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553473 | REC_0010475 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.3 | 59 | male | 0 | 13 | 6 | 6 | alectinib 600 mg BID | 15.4 | false | MSS | 2026-03-15T05:35:59.470832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544027 | REC_0010476 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.9 | 47 | male | 0 | 50 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.8 | false | MSS | 2026-03-15T05:35:59.471079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262452 | REC_0010477 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8.4 | 59 | female | 1 | 14 | 6.7 | 6 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:59.471316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252851 | REC_0010478 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 11.6 | 56 | male | 1 | 17 | 4.8 | 0 | osimertinib 80 mg daily | 40.8 | false | MSS | 2026-03-15T05:35:59.471560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433105 | REC_0010479 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13 | 57 | male | 1 | 23 | 7.2 | 6 | sotorasib 960 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:59.471908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513710 | REC_0010480 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.7 | 63 | male | 0 | 11 | 2 | 7 | entrectinib 600 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:59.472211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602734 | REC_0010481 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 24 | 11.9 | 63 | female | 0 | 11 | 4.3 | 0 | pembrolizumab 200 mg q3w | 34.9 | true | MSI-H | 2026-03-15T05:35:59.472457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201612 | REC_0010482 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 3.6 | 57 | male | 0 | 31 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.3 | true | MSS | 2026-03-15T05:35:59.472691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238742 | REC_0010483 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 15.1 | 58 | male | 0 | 5 | 6.2 | 4 | entrectinib 600 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:35:59.472927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791956 | REC_0010484 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 16.3 | 58 | female | 0 | 15 | 7.2 | 7 | alectinib 600 mg BID | 9.9 | false | MSI-H | 2026-03-15T05:35:59.473166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370767 | REC_0010485 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 6.6 | 65 | female | 0 | 7 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.5 | true | MSS | 2026-03-15T05:35:59.473405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648088 | REC_0010486 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 7.8 | 77 | female | 0 | 50 | 4.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 43.3 | false | MSS | 2026-03-15T05:35:59.473633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549532 | REC_0010487 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 20.6 | 58 | female | 0 | 24 | 5.7 | 4 | alectinib 600 mg BID | 13.8 | false | MSS | 2026-03-15T05:35:59.473873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175109 | REC_0010488 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 6.4 | 63 | female | 1 | 16 | 6.3 | 1 | osimertinib 80 mg daily | 24 | true | MSS | 2026-03-15T05:35:59.474108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735497 | REC_0010489 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 14.3 | 73 | female | 1 | 18 | 7 | 1 | sotorasib 960 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:35:59.474341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295188 | REC_0010490 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 14.2 | 70 | female | 1 | 26 | 4.4 | 4 | alectinib 600 mg BID | 7.9 | false | MSS | 2026-03-15T05:35:59.474578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439485 | REC_0010491 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 16 | 8.9 | 68 | female | 1 | 14 | 5.4 | 6 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:35:59.474807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726430 | REC_0010492 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.2 | 74 | female | 3 | 7 | 5.7 | 8 | pembrolizumab 200 mg q3w | 14.6 | false | MSS | 2026-03-15T05:35:59.475117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435932 | REC_0010493 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 2.4 | 67 | female | 0 | 9 | 6 | 6 | osimertinib 80 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:59.475354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777277 | REC_0010494 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.6 | 77 | male | 1 | 48 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.1 | false | MSS | 2026-03-15T05:35:59.475588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647261 | REC_0010495 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 9.4 | 76 | female | 2 | 16 | 2.6 | 1 | entrectinib 600 mg daily | 11 | false | MSS | 2026-03-15T05:35:59.475817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649870 | REC_0010496 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12 | 77 | female | 1 | 18 | 4.4 | 2 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.476148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449819 | REC_0010497 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 14.3 | 67 | female | 0 | 15 | 6.7 | 5 | osimertinib 80 mg daily | 6.9 | false | MSI-H | 2026-03-15T05:35:59.476411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670215 | REC_0010498 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11 | 74 | male | 1 | 11 | 6.9 | 5 | pembrolizumab 200 mg q3w | 11.6 | false | MSI-H | 2026-03-15T05:35:59.476671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800716 | REC_0010499 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 8.2 | 85 | female | 2 | 63 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.1 | true | MSS | 2026-03-15T05:35:59.476957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508068 | REC_0010500 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.6 | 53 | female | 0 | 31 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.9 | false | MSS | 2026-03-15T05:35:59.477197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.